Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Two blood cancers treated successfully with immunotherapy

12 June 2017

By Ebtehal Moussa

Appeared in BioNews 904

Two trials of a new gene therapy have successfully treated blood cancers in patients who were unresponsive to standard treatment.

The therapy, known as CAR-T cell therapy, involves taking a blood sample from a patient, extracting immune system cells called T-cells from it, genetically modifying them in the laboratory so they can detect and kill cancer cells better, then injecting them back into the patient. The modified T-cells remain in a patient's body, multiplying and providing long-term protection.

One study, led by Professor Carl June of the University of Pennsylvania, was centered on ten patients with chronic lymphocytic leukemia (CLL). Over 3500 GLINK(454940, diagnoses)} of CLL are made yearly in the UK and result in over 1000 deaths.

All patients in the study had mutations associated with high-risk CLL and were unresponsive to the standard drug treatment of ibrutinib. During the trial patients received a combination of ibrutinib and a CAR-T cell therapy called CTL119 over three consecutive days.

After three months, there was no evidence of disease in eight of nine patients who could be evaluated. All eight patients remained without signs of disease at a median of six months after treatment.

The study's first author, Dr Saar Gill of the University of Pennsylvania, explained: 'Combining ibrutinib with the CTL119 therapy achieved very powerful results for these patients, and with limited toxicity. This newer, coupled approach gives us hope that personalized cell therapies could be an important option for high-risk CLL patients on these types of drugs.'

In a second trial, researchers at Xi'an Jiaotong University, China, gave CAR-T cell therapy over a week to 35 patients with multiple myeloma, another type of blood cancer, who were not responding to standard treatment. Over 115,000 diagnoses of multiple myeloma are made each year worldwide.

Ten days after treatment all patients displayed a reduction in cancer size, and 33 patients showed clinical remission within two months of treatment.

Of 19 patients who could be evaluated after four months, 14 achieved a complete loss of evidence of disease (complete response), and five achieved partial response. Five of the patients with a complete response remain disease-free a year later.

The researchers intend to expand the study to include 100 people in China, and launch another study in the US.

'Although recent advances in chemotherapy have prolonged life expectancy in multiple myeloma, this cancer remains incurable,' said study author Dr Wanhong Zhao of Xi'an Jiaotong University. 'It appears that with this novel immunotherapy there may be a chance for cure in multiple myeloma, but we will need to follow patients much longer to confirm that.'

Patients from both studies experienced side effects of CAR T-cell therapy, but this was manageable in all patients.

The two clinical trials were presented at the 2017 American Society of Clinical Oncology Annual Meeting.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 November 2017 - by Dr Patrick Foong 
Stem cell research holds tremendous promise for the treatment of a wide variety of illnesses and conditions, from spinal cord injury to autism. However, much more work is necessary to translate stem cell research into safe and effective therapies...
11 September 2017 - by Ebtehal Moussa 
Two trials assessing gene therapy for blood cancer have been put on hold by the US Food and Drug Administration, following a patient fatality...
14 August 2017 - by Ebtehal Moussa 
Over a 100 new genes that may be essential for cancer immunotherapy to work have been identified using a new CRISPR-based screen...
17 July 2017 - by Dr Loredana Guglielmi 
A drug for leukaemia that genetically alters patients' own cells to fight cancer, has cleared a critical hurdle in gaining commercial approval...

06 March 2017 - by Annabel Slater 
A trial gene therapy has reversed terminal blood cancer in a third of patients...
25 January 2017 - by Dr Loredana Guglielmi 
Doctors at London's Great Ormond Street Hospital have used genome editing to successfully treat two children with leukaemia...
12 December 2016 - by Ayala Ochert and Ebtehal Moussa 
Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...
24 February 2014 - by Chris Hardy 
Researchers trialling a gene therapy-based treatment for leukemia have said the early results go beyond anything they could have thought of in their 'wildest dreams'...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation